Louisiana State Employees Retirement System decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 79,100 shares of the biopharmaceutical company’s stock after selling 2,400 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Gilead Sciences were worth $5,667,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of GILD. Welch Investments LLC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $108,000. Wealthcare Advisory Partners LLC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $133,000. Horan Capital Advisors LLC. acquired a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $144,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $147,000. Finally, Hanson & Doremus Investment Management increased its holdings in shares of Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares during the last quarter. 76.47% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Gilead Sciences, Inc. (GILD) opened at $80.70 on Friday. The firm has a market capitalization of $105,415.91, a price-to-earnings ratio of 23.19, a PEG ratio of -1.85 and a beta of 1.22. The company has a current ratio of 3.55, a quick ratio of 3.48 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $89.54.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.83%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is presently 59.77%.
In related news, EVP James R. Meyers sold 100,000 shares of the company’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total transaction of $8,024,000.00. Following the completion of the sale, the executive vice president now directly owns 102,715 shares in the company, valued at approximately $8,241,851.60. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Gayle E. Wilson sold 60,000 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $77.92, for a total value of $4,675,200.00. Following the sale, the director now owns 182,258 shares of the company’s stock, valued at $14,201,543.36. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 418,333 shares of company stock valued at $32,742,108. Corporate insiders own 1.30% of the company’s stock.
A number of research analysts recently weighed in on the company. ValuEngine raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Credit Suisse Group set a $80.00 target price on Gilead Sciences and gave the stock a “hold” rating in a report on Wednesday, January 3rd. Leerink Swann decreased their price objective on Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating on the stock in a report on Wednesday, February 7th. Mizuho upped their price objective on Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, November 8th. Finally, BMO Capital Markets decreased their price objective on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a report on Friday, October 27th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $87.04.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.